Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2022 - 05 - 16 symbols : SNYNF save search
Global RSV Vaccine and Antibody Pipeline Market: Compound Annual Growth of 38.9% Forecast During 2024-2028
Published: 2022-05-16 (Crawled : 19:00) - prnewswire.com
AZNCF | News | $140.3 -4.19% 1.5K
|
Health Technology
|
| O: 4.22%
H: 0.0%
C: -2.05%
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: 1.08%
H: 0.0%
C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 1.5%
H: 0.64%
C: 0.19%
AZN | News | $71.175 0.46% 0.46% 6.1M
|
Health Technology
|
| O: 3.17%
H: 0.0%
C: 0.0%
antibody vaccine growth
Positive Clinical Results Advance Treatments For Multiple Myeloma, Asthma, Alzheimer’s
Published: 2022-05-16 (Crawled : 17:00) - biospace.com/
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.41%
H: 0.0%
C: 0.0%
alzheimer’s positive treatment alzheimer's
Positive Clinical Results Advance Treatments For Multiple Myeloma, Asthma, Al...
Published: 2022-05-16 (Crawled : 17:00) - biospace.com/
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.41%
H: 0.0%
C: 0.0%
positive treatment
Exciting Advancements in Multiple Myeloma, Asthma and Alzheimer’s
Published: 2022-05-16 (Crawled : 17:00) - biospace.com/
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.41%
H: 0.0%
C: 0.0%
alzheimer’s alzheimer's
Elicio Therapeutics Announces Clinical Supply Agreement with Regeneron to Evaluate ELI-002 in Combination with Libtayo® (cemiplimab) in KRAS-Driven Tumors
Published: 2022-05-16 (Crawled : 15:00) - biospace.com/
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.41%
H: 0.0%
C: 0.0%
eli-002 libtayo therapeutics
Clinical Catch-Up: Updates for Achilles, Logic Bio, Roche and More
Published: 2022-05-16 (Crawled : 13:00) - biospace.com/
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.41%
H: 0.0%
C: 0.0%
Atamyo Therapeutics Announces Significant Milestones for ATA-100 and ATA-200, its Gene Therapy Programs to Treat Limb-Girdle Muscular Dystrophy 2I/R9 and 2C/R5
Published: 2022-05-16 (Crawled : 08:00) - biospace.com/
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.41%
H: 0.0%
C: 0.0%
ata-100 therapeutics therapy
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.